HomeBest Practices → 23andMe Receives FDA Nod

23andMe Receives FDA Nod Print E-mail
Written by FHI's Week in Review   
Monday, 10 April 2017 16:49

According to an news release dated 4.6.17:
The U.S. Food and Drug Administration (FDA) today allowed marketing of 23andMe Personal Genome Service Genetic Health Risk (GHR) tests for 10 diseases or conditions. These are the first direct-to-consumer (DTC) tests authorized by the FDA that provide information on an individual's genetic predisposition to certain medical diseases or conditions, which may help to make decisions about lifestyle choices or to inform discussions with a health care professional.

Read more in the current issue of Week in Review>>

Last Updated on Monday, 01 May 2017 18:12

Website design, development, and hosting provided by